ABOS (Acumen Pharmaceuticals) Total Operating Expense: $114.61 Mil (TTM As of Mar. 2026)


ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.36
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals Total Operating Expense?

Acumen Pharmaceuticals ABOS +6.79% 34 Total Operating Expense is $114.61 Mil as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Acumen Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was $21.15 Mil. Acumen Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $114.61 Mil.

Acumen Pharmaceuticals Total Operating Expense Related Terms

Acumen Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals Total Operating Expense Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 19.58 45.24 61.14 114.02 123.83

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.37 41.75 26.51 25.20 21.15
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $114.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $114.61 Mil mean?
Acumen Pharmaceuticals (ABOS) has a Total Operating Expense of $114.61 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' Total Operating Expense too high?
Acumen Pharmaceuticals' current Total Operating Expense is $114.61 Mil. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' Total Operating Expense compare to QTTB and TNYA?
Acumen Pharmaceuticals' Total Operating Expense of $114.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current Total Operating Expense is $114.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current Total Operating Expense of $114.61 Mil. The current Total Operating Expense is $114.61 Mil. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current Total Operating Expense is $114.61 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.36
Price